We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Common Contracts

3 similar Research and Development Collaboration, Option, and License Agreement contracts by OncoMed Pharmaceuticals Inc

EX-10.1(A) 2 d344523dex101a.htm RESEARCH AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT Execution Version
Research and Development Collaboration, Option, and License Agreement • May 5th, 2020 • Delaware

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

AutoNDA by SimpleDocs
RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENT BY AND BETWEEN ONCOMED PHARMACEUTICALS, INC. AND SMITHKLINE BEECHAM CORPORATION DECEMBER 7, 2007
Research and Development Collaboration, Option, and License Agreement • July 5th, 2012 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

THIS RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENT (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of December 7, 2007 (the “Effective Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and SmithKline Beecham Corporation, a Pennsylvania corporation doing business as GlaxoSmithKline with a principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19102, United States of America (“GSK”). OncoMed and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENT BY AND BETWEEN ONCOMED PHARMACEUTICALS, INC. AND SMITHKLINE BEECHAM CORPORATION DECEMBER 7, 2007
Research and Development Collaboration, Option, and License Agreement • May 11th, 2012 • OncoMed Pharmaceuticals Inc • Delaware

THIS RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENT (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of December 7, 2007 (the “Effective Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and SmithKline Beecham Corporation, a Pennsylvania corporation doing business as GlaxoSmithKline with a principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19102, United States of America (“GSK”). OncoMed and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!